Recombinant chimeric (human/Mouse) antibody expressed in CHO binding to human GD2. Dinutuximab is a chimeric monoclonal antibody that induces antibody dependent cell-mediated cytotoxicity. Dinutuximab is intended as maintenance therapy (targeting minimal residual disease) for high risk neuroblastoma, administered after induction therapy, autologous stem cell transplantation and/or radiotherapy.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.